Literature DB >> 28664928

Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation.

Adam G Walker1,2, Douglas J Sheffler3, Andrew S Lewis1,2, Jonathan W Dickerson1,2, Daniel J Foster1,2, Rebecca K Senter1,2, Mark S Moehle1,2, Xiaohui Lv1,2, Branden J Stansley1,2, Zixiu Xiang1,2, Jerri M Rook1,2, Kyle A Emmitte1,2,4, Craig W Lindsley1,2,4, P Jeffrey Conn1,2.   

Abstract

Activation of β-adrenergic receptors (βARs) enhances both the induction of long-term potentiation (LTP) in hippocampal CA1 pyramidal cells and hippocampal-dependent cognitive function. Interestingly, previous studies reveal that coincident activation of group II metabotropic glutamate (mGlu) receptors with βARs in the hippocampal astrocytes induces a large increase in cyclic-AMP (cAMP) accumulation and release of adenosine. Adenosine then acts on A1 adenosine receptors at neighboring excitatory Schaffer collateral terminals, which could counteract effects of activation of neuronal βARs on excitatory transmission. On the basis of this, we postulated that activation of the specific mGlu receptor subtype that mediates this response could inhibit βAR-mediated effects on hippocampal synaptic plasticity and cognitive function. Using novel mGlu receptor subtype-selective allosteric modulators along with knockout mice we now report that the effects of mGlu2/3 agonists on βAR-mediated increases in cAMP accumulation are exclusively mediated by mGlu3. Furthermore, mGlu3 activation inhibits the ability of the βAR agonist isoproterenol to enhance hippocampal LTP, and this effect is absent in slices treated with either a glial toxin or an adenosine A1 receptor antagonist. Finally, systemic administration of the mGlu2/3 agonist LY379268 disrupted contextual fear memory in a manner similar to the effect of the βAR antagonist propranolol, and this effect was reversed by the mGlu3-negative allosteric modulator VU0650786. Taken together, these data suggest that mGlu3 can influence astrocytic signaling and modulate βAR-mediated effects on hippocampal synaptic plasticity and cognitive function.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28664928      PMCID: PMC5686489          DOI: 10.1038/npp.2017.136

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  51 in total

1.  ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression.

Authors:  Jing-ming Zhang; Hui-kun Wang; Chang-quan Ye; Wooping Ge; Yiren Chen; Zheng-lin Jiang; Chien-ping Wu; Mu-ming Poo; Shumin Duan
Journal:  Neuron       Date:  2003-12-04       Impact factor: 17.173

Review 2.  G protein-coupled receptor signalling in astrocytes in health and disease: a focus on metabotropic glutamate receptors.

Authors:  Sophie J Bradley; R A John Challiss
Journal:  Biochem Pharmacol       Date:  2012-04-15       Impact factor: 5.858

3.  The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Authors:  Corrado Corti; Giuseppe Battaglia; Gemma Molinaro; Barbara Riozzi; Anna Pittaluga; Mauro Corsi; Manolo Mugnaini; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

4.  GFAP-positive progenitor cells produce neurons and oligodendrocytes throughout the CNS.

Authors:  Kristen B Casper; Ken D McCarthy
Journal:  Mol Cell Neurosci       Date:  2006-02-03       Impact factor: 4.314

5.  The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling.

Authors:  V Bruno; F X Sureda; M Storto; G Casabona; A Caruso; T Knopfel; R Kuhn; F Nicoletti
Journal:  J Neurosci       Date:  1997-03-15       Impact factor: 6.167

6.  Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Authors:  Filippo Caraci; Gemma Molinaro; Giuseppe Battaglia; Maria Laura Giuffrida; Barbara Riozzi; Anna Traficante; Valeria Bruno; Milena Cannella; Sara Merlo; Xushan Wang; Beverly A Heinz; Eric S Nisenbaum; Thomas C Britton; Filippo Drago; Maria Angela Sortino; Agata Copani; Ferdinando Nicoletti
Journal:  Mol Pharmacol       Date:  2010-12-15       Impact factor: 4.436

7.  Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.

Authors:  Ruggero Galici; Carrie K Jones; Kamondanai Hemstapat; Yi Nong; Nicholas G Echemendia; Lilly C Williams; Tomas de Paulis; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2006-04-11       Impact factor: 4.030

8.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).

Authors:  Cody J Wenthur; Ryan Morrison; Andrew S Felts; Katrina A Smith; Julie L Engers; Frank W Byers; J Scott Daniels; Kyle A Emmitte; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

9.  Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration.

Authors:  V Bruno; G Battaglia; A Copani; R G Giffard; G Raciti; R Raffaele; H Shinozaki; F Nicoletti
Journal:  Eur J Neurosci       Date:  1995-09-01       Impact factor: 3.386

10.  Pharmacological differentiation of the effects of co-activation of beta-adrenergic and metabotropic glutamate receptors in rat hippocampus.

Authors:  R W Gereau; D G Winder; P J Conn
Journal:  Neurosci Lett       Date:  1995-02-17       Impact factor: 3.046

View more
  8 in total

1.  Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Authors:  Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-06-08       Impact factor: 4.418

Review 2.  Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.

Authors:  Branden J Stansley; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-02-26       Impact factor: 14.819

3.  Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome.

Authors:  Sheryl Anne D Vermudez; Aditi Buch; Kelly Weiss; Rocco G Gogliotti; Colleen M Niswender
Journal:  Neuropharmacology       Date:  2022-03-03       Impact factor: 5.250

Review 4.  The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.

Authors:  Branden J Stansley; P Jeffrey Conn
Journal:  Curr Opin Pharmacol       Date:  2018-02-24       Impact factor: 5.547

Review 5.  The Unexplored Territory of Neural Models: Potential Guides for Exploring the Function of Metabotropic Neuromodulation.

Authors:  Michael E Hasselmo; Andrew S Alexander; Alec Hoyland; Jennifer C Robinson; Marianne J Bezaire; G William Chapman; Ausra Saudargiene; Lucas C Carstensen; Holger Dannenberg
Journal:  Neuroscience       Date:  2020-04-08       Impact factor: 3.590

Review 6.  Developing neuroscience-based treatments for alcohol addiction: A matter of choice?

Authors:  Markus Heilig; Eric Augier; Simone Pfarr; Wolfgang H Sommer
Journal:  Transl Psychiatry       Date:  2019-10-08       Impact factor: 6.222

Review 7.  Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.

Authors:  Tanja Veselinović; Irene Neuner
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

Review 8.  Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2021-06-25       Impact factor: 5.273

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.